Michael S. Rabin

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

Priscilla K. Brastianos, Scott L. Carter, Sandro Santagata et al. · Cancer Discovery · 2015 · 1.1K citations · Full text

Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham et al. · JAMA Oncology · 2018 · 673 citations · Full text

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

David M. Jackman, Beow Y. Yeap, Lecia V. Sequist et al. · Clinical Cancer Research · 2006 · 583 citations

Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer

David M. Jackman, Beow Y. Yeap, Neal I. Lindeman et al. · Journal of Clinical Oncology · 2007 · 306 citations

Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression

Stanley R. Riddell, Michael S. Rabin, Adam P. Geballe et al. · The Journal of Immunology · 1991 · 232 citations